Get the Stockscreener App
1.71
6.21%
0.10
After Hours:
1.70
-0.01
-0.58%
Invivyd Inc stock is traded at $1.71, with a volume of 1.63M.
It is up +6.21% in the last 24 hours and down -1.72% over the past month.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
See More
Previous Close:
$1.61
Open:
$1.63
24h Volume:
1.63M
Relative Volume:
0.52
Market Cap:
$483.59M
Revenue:
$53.43M
Net Income/Loss:
$-52.49M
P/E Ratio:
-4.7646
EPS:
-0.3589
Net Cash Flow:
$-58.29M
1W Performance:
+26.67%
1M Performance:
-1.72%
6M Performance:
-2.29%
1Y Performance:
+232.68%
1-Day Range:
$1.62
$1.735
1-Week Range:
$1.39
$1.80
52-Week Range:
$0.4613
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
209 CHURCH STREET, NEW HAVEN
Compare IVVD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.71 | 455.31M | 53.43M | -52.49M | -58.29M | -0.3589 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
View All
Invivyd Inc Stock (IVVD) Latest News
Invivyd rises after update from late-stage trial for COVID therapy - MSN
Invivyd stock surges as FDA alignment boosts COVID-19 program - MSN
Aug Reactions: What are Invivyd Incs technical support levelsLayoff News & Expert-Curated Trade Recommendations - baoquankhu1.vn
Invivyd: Why The Trial Upsizing Isn't The Green Light Bulls Think It Is (NASDAQ:IVVD) - Seeking Alpha
Authentic virus research in labs faces adaptation hurdles, Invivyd, Inc. asserts - Traders Union
Invivyd unveils measles monoclonal antibody candidate VMS-063 - BioWorld News
H.C. Wainwright reiterates Invivyd stock rating on measles program By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Invivyd stock rating on measles program - Investing.com
Invivyd upsizes COVID-19 trial, targets measles antibody By Investing.com - Investing.com Australia
Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody CandidateSlideshow (NASDAQ:IVVD) 2026-04-09 - Seeking Alpha
Invivyd Updates VYD2311 REVOLUTION Trials, Modestly Upsizes Study, Unveils Measles mAb VMS-063 - MarketBeat
Invivyd reveals plans to test an antibody drug against measles - BioPharma Dive
Invivyd posts update from late-stage COVID trial (IVVD:NASDAQ) - Seeking Alpha
Invivyd stock surges 25% on COVID-19 trial progress By Investing.com - Investing.com Australia
Invivyd stock surges 25% on COVID-19 trial progress - Investing.com
Invivyd Stock Surges As FDA Alignment Boosts COVID-19 ProgramInvivyd (NASDAQ:IVVD) - Benzinga
Invivyd Advances COVID-19 and Measles Monoclonal Antibody Programs With Phase 3 Updates and New VMS063 Candidate for Measles Prevention and Treatment 1 - Minichart
Invivyd Advances COVID-19 Program and Launches Measles Antibody - TipRanks
Invivyd upsizes DECLARATION Phase 3, delays topline to Q3 2026; advances measles mAb VMS063 toward IND - TradingView
Invivyd upsizes COVID-19 trial, targets measles antibody - Investing.com
Invivyd (IVVD) expands VYD2311 Phase 3 and pushes potent measles antibody VMS063 toward clinic - Stock Titan
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles - The Manila Times
As measles resurges, Invivyd advances antibody and delays COVID data - Stock Titan
Invivyd, Inc. outlines antibody response as critical for immune defense actions - Traders Union
Surprises Report: What makes Invivyd Inc stock attractive todayQuarterly Portfolio Review & Low Risk Entry Point Guides - baoquankhu1.vn
Invivyd Launches "Antibodies for Any Body" in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health - Bitget
Invivyd Launches 'Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health - The Manila Times
Lindsey Vonn joins Invivyd's antibody education campaign - Stock Titan
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Invivyd, Inc. (IVVD) Reports Q3 Loss, Lags Revenue Estimates - MSN
Invivyd (NASDAQ: IVVD) plans 2026 virtual meeting and auditor vote - Stock Titan
16 new Invivyd hires get stock options at $1.33 exercise price - Stock Titan
IVVD Technical Analysis & Stock Price Forecast - Intellectia AI
Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Invivyd Inc. (IVVD) Stock Price Quote Today & Current Price Chart - Capital.com
Joel Greenblatt's Invivyd Inc(IVVD) Holding History - gurufocus.com
Invivyd Announces Presentation at the World Vaccine Congress Washington - The Manila Times
At vaccine congress, Invivyd says antibody drugs can track viral shifts - Stock Titan
Investment Recap: What makes Invivyd Inc stock attractive today2026 Short Interest & High Yield Equity Trading Tips - baoquankhu1.vn
Exploring Three High Growth Tech Stocks In The US Market - simplywall.st
Analysis Recap: What is the target price for Invivyd Inc stockTrade Signal Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
HC Wainwright & Co. Maintains Invivyd (IVVD) Buy Recommendation - MSN
Insider Buy: How liquid is Invivyd Inc stock2026 Breakouts & Breakdowns & Weekly Top Performers Watchlists - baoquankhu1.vn
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):